PTO/SB/08a (11-08)
Approved for use through 12/31/2008 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number		10581656	
	Filing Date		2008-06-09	
	First Named Inventor Hyun		rung-Joo Kwon	
	Art Unit		1645	
	Examiner Name	Oguni	bıyi, O.	
	Attorney Docket Numb	er	BARUN-10974	

U.S.PATENTS						Kemove					
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	Date	Name of Pate of cited Docu	entee or Applicant ment				
	1	6406705		2002-06	i-18	University of Id	University of Iowa Whole Do				
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	Releva	s,Columns,Lines where rant Passages or Relevant es Appear			
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Kind Code <sup>2</sup> j		Publication Date	Name of Patente Applicant of cited Document			TS		
	1	199840100	wo			1998-09-17	Davis, et al.	,	Whole Doc	ument	
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(e), volume-issue number(s), publisher, city and/or country where published.							Т				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10581656		
Filing Date		2008-06-09		
First Named Inventor	Hyung-Joo Kwon			
Art Unit		1645		
Examiner Name	Ogunbiyi, O.			
Attorney Docket Number		BARUN-10974		

1	AKDIS, et al., "Immune regulation in atopic dermatitis." Curr Opin Immunol, 2000 Dec; 12(6):641-6	
2	KIVON, et al., "NF-kappaB-dependent regulation of tumor necrosis factor-alpha gene expression by CpG- oligodeoxynucleolides." Blochem Biophys Res Commun. 2009 Nov 7,311(1):129-38	
3	DENG, et al., "The features of arthritis induced by CpG molifs in backerial DNA." Arthritis Rheum. 2000 Feb;43 (2):356-64	
4	TANAKA, et al., "An antisense oligonuciectide complementary to a sequence in I gamma 2b increases gamma 2b germline transcrpts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion" J Exp Med. 1992 Feb 1,175(2):997-607	
5	DAVIS, et al., "CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen." J Immunol. 1998 Jan 15;160(2):870-6	
6	RUDIKOFF, et al., "Atopio dermatifis." Lancet. 1998 Jun 6;351(9117):1715-21	
7	IMOKAWA, et al., "Decreased level of ceramides in stratum comeum of atopic dermatifis: an etologic factor in atopic dry skin?" J Invest Dermatol. 1991 Apr;96(4) 523-8	
8	ASH/WELL, et al., "Effect of gamma radiation on resting B lymphocytes. I. Oxygen-dependent damage to the plasma membrane results in increased permeability and cell enlargement." J Immunol. 1986 May 15; 136;(10):3649-56	
9	PROSSER "Survival of human T and B lymphocytes after X-arradiation." Int. J Radiat Biol Relat Stud Phys Chem Med. 1976 Nov.;30(5) 459-65	
10	KUBOTA, et al., "Radiation-induced apoplosis in perifoneal resident macrophages of C3H mice" J Radiat Res (Tokyo). 2004 Jun;45(2):205-11	
11	KRIEG, A.M., "CpG modified in bacterial DNA and their immune effects" Annu. Rev. Immunol, 2002, Vol. 20709-742	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

plication Number		10581656		
ling Date		2008-06-09		
rst Named Inventor	Hyun	g-Joo Kwon		
t Unit		1645		
caminer Name	Ogunbiyi, O.			
tomey Docket Number		BARUN-10974		

	12	KRIEG, et al, "CpG motifs in bacterial DNA trigger direct B-cell activation" 1995, nature vol 374, p546-549	
	13	UHLIMANN, et al., "Recent advances in the development of immunostimulatory oligonucleoides" (2003-03), CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT MAR 2003, vol. 6, no. 2, pages 204-217	
	14	KRIEG, et al., "Mechanism of Action of CpG DNA" (2000-01-01), CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, SPRINGER, BERLIN, DE, vol. 247, 1, pages 1-21	
	15	BALLAS, et al. "Induction of NK activity in mume and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA" J Immunol. 1996 Sep 1;157(5):1840-5	
	16	KLINMAN, et al. "CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interieukin 6, interieukin 12, and interferon gamma" Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-53	
If you wis	h to a	d additional non-patent literature document citation information please click the Add button Add	$\neg$

Examiner Signature	Date Considered	i

F

E

EXAMINER SIGNATURE \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.